LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Strona główna・Stock List・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Closed

9.19 -2.85

Buy Sell

Overview

Share price change

24h

Current

Min

9.1

Max

9.38

Key metrics
By Trading Economics
Income	4.2M -23M
Profit margin	-2,027.003
Employees	79
EBITDA	4.5M -25M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+47.78% upside

Market Stats
By TradingEconomics
Market Cap	72M 659M
Previous open	12.04
Previous close	9.19

Ventyx Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lis 2025, 17:45 UTC

Earnings

Major Market Movers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 lis 2025, 17:31 UTC

Earnings

Major Market Movers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 lis 2025, 16:15 UTC

Major Market Movers

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

15 lis 2025, 09:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

15 lis 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15 lis 2025, 00:08 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 lis 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 lis 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 lis 2025, 22:35 UTC

Earnings

Acquisitions, Mergers, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 lis 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 lis 2025, 22:29 UTC

Earnings

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 lis 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 lis 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

14 lis 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 lis 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 lis 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 lis 2025, 20:17 UTC

Acquisitions, Mergers, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 lis 2025, 19:29 UTC

Market Talk

Earnings

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 lis 2025, 18:44 UTC

Market Talk

Earnings

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 lis 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

14 lis 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 lis 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 lis 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 lis 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 lis 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 lis 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

Peer Comparison

Price change

Ventyx Biosciences Inc Forecast

Price Target

By TipRanks

47.78% upside

12 Months Forecast

Average 13.67 USD 47.78%

High 21 USD

Low 2 USD

Based on 7 Wall Street analysts offering 12 month price targets forVentyx Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Ventyx Biosciences Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.